Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov
Health Capsule
Antibodies Protect Against Range of Flu Viruses
Scientists isolated Germ-fighting molecules made by the body antibodies that protect mice against several deadly flu viruses. The accomplishment is a step toward a flu vaccine that can protect against multiple viral strains for several years.
Flu is caused by influenza viruses, which infect the nose, throat and lungs. These viruses constantly change, or mutate. Researchers need to reformulate the flu vaccine each year to match new strains. If a vaccine could prompt the body to make antibodies that latch onto unchanging parts of the virus, it might provide long-lasting protection.
NIH-funded researchers previously isolated antibodies that target a wide range of influenza “type A” viruses. Type A viruses are responsible for avian flu, the 1918 pandemic flu and seasonal flu.
In the new study, scientists took a similar approach to find antibodies that neutralize influenza “type B” viruses. Influenza B viruses have received less attention. They’re less likely to cause worldwide outbreaks. But they can cause seasonal flu.
Researchers collected and tested antibodies from people recently vaccinated for seasonal flu. The scientists identified 3 antibodies that latched onto a specific region on different influenza B viruses. One of these 3 also bound type A viruses.
All 3 antibodies protected mice from deadly influenza B viruses. The broader-binding one also guarded against lethal doses of 2 types of influenza A viruses.
“To develop a truly universal flu vaccine or therapy, one needs to be able to provide protection against influenza A and influenza B viruses,” says one of the head authors, Dr. Ian A. Wilson of the Scripps Research Institute. “With this report, we now have broadly neutralizing antibodies against both.”
NIH Office of Communications and Public Liaison
Health and Science Publications Branch
Building 31, Room 5B52
Bethesda, MD 20892-2094
Contact Us:
nihnewsinhealth@od.nih.gov
Phone: 301-451-8224
Share Our Materials: Reprint our articles and illustrations in your own publication. Our material is not copyrighted. Please acknowledge NIH News in Health as the source and send us a copy.
For more consumer health news and information, visit health.nih.gov.
For wellness toolkits, visit www.nih.gov/wellnesstoolkits.
